Indiana University brings multidisciplinary research teams with expertise in translational sciences along with streamlined resources, efficient services, and an institutional environment that fosters innovative clinical and translational research to the NCTN. IU investigators have left trials that defined the standard of care in thymoma, testes, pancreas, and breast cancer. We are committed to leading and supporting the next generation of translational trials within the National Clinical Trial Network. As a Lead Academic Participating Site we will pursue four specific aims: 1) Integrate genomics, pharmacogenomics, and other molecular assays with traditional histopathology to individualize therapy, 2) Lead clinical and translational research in key rare tumors, 3) Use the cooperative groups to further cancer survivorship research, and 4) Mentor junior faculty members. To accomplish those specific aims, we have redesigned and consolidated the clinical trial infrastructure to function with greater efficiency and cost-effectiveness while still meeting the needs of investigators. Overall leadership of the NCTN at lU is vested in Dr. Kathy Miller, a seasoned investigator who has led three national trials coordinated by ECOG. Dr. Miller enjoys widespread institutional and multidisciplinary support and is fully empowered to leverage resources needed to facilitate accrual and movement of IU translational science forward to the NCTN. She is joined by key investigators in Hematology/Oncology, Gynecologic Oncology, Radiation Oncology, Surgery, Pathology, Nursing, and Urology. In this application IU will be joined by four affiliates 1) The Richard A Roudebush VA Medical Center, 2) IU Health Ball Memorial Hospital, 3) IU Health Central Indiana Cancer Centers, and 4) IU Health Goshen. IU accrual averages ~100 patients per year over the most recent 5 year period with participation in ECOG (~65%), GOG (~25%), and ACOSOG (~10%). In addition IU investigators have held key leadership roles within ECOG and the GOG and have made key scientific contributions employing biologic specimens banked as part of cooperative group trials.

Public Health Relevance

The lUSCC is the only NCI-Designated Cancer Center that treats patients in Indiana. Our long standing commitment for clinical research has been illustrated by pilot trials conducted at lUSCC and taken to the cooperative oncology groups (ECOG) for definitive testing. Standards of care for the treatment of germ cell tumors, lung cancer, thymoma and breast cancer have emerged from trials led by IU investigators

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180795-04
Application #
9238458
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-06-01
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
4
Fiscal Year
2017
Total Cost
$519,002
Indirect Cost
$173,190
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087
Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382
Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369
Wong, Yu-Ning; Manola, Judith; Hudes, Gary R et al. (2018) Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer 16:e315-e322
Cohee, Andrea A; Bigatti, Silvia M; Shields, Cleveland G et al. (2018) Quality of Life in Partners of Young and Old Breast Cancer Survivors. Cancer Nurs 41:491-497
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Marcelletti, John F; Sikic, Branimir I; Cripe, Larry D et al. (2018) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom :

Showing the most recent 10 out of 41 publications